Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Tumor Biology

• Publication date

  2015-07-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s13277-015-3747-xPMID 26150340
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RETRACTED ARTICLE: Pttg1 inhibits TGFβ signaling in breast cancer cells to promote their growth

  2014cited by this paper
• PTTG1 inhibits SMAD3 in prostate cancer cells to promote their proliferation

  2014cited by this paper
• Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience

  2014cited by this paper
• RETRACTED ARTICLE: Inhibition of FoxO1 nuclear exclusion prevents metastasis of Glioblastoma

  2014influential reference
• RETRACTED ARTICLE: MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma

  2014cited by this paper
• M2 macrophages promote beta-cell proliferation by up-regulation of SMAD7

  2014cited by this paper
• EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2

  2014cited by this paper
• HDAC inhibitor DWP0016 activates p53 transcription and acetylation to inhibit cell growth in U251 glioblastoma cells

  2013influential reference
• TGFβ Receptor Signaling Is Essential for Inflammation-Induced but Not β-Cell Workload–Induced β-Cell Proliferation

  2013cited by this paper
• HDAC inhibitors and their potential applications to glioblastoma therapy

  2013influential reference
• USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma

  2012cited by this paper
• Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.

  2012influential reference
• Transforming growth factor β1 inhibits bone morphogenic protein (BMP)-2 and BMP-7 signaling via upregulation of Ski-related novel protein N (SnoN): possible mechanism for the failure of BMP therapy?

  2012cited by this paper
• P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells

  2012influential reference
• Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

  2012cited by this paper
• Nuclear Smad7 Overexpressed in Mesenchymal Cells Acts as a Transcriptional Corepressor by Interacting with HDAC-1 and E2F to Regulate Cell Cycle

  2012cited by this paper
• Epigenetic regulation of myofibroblast differentiation and extracellular matrix production in nasal polyp‐derived fibroblasts

  2012cited by this paper
• MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma.

  2011cited by this paper
• Blockade of TGF-beta signaling by the TGF β R-I kinase Inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma

  2011cited by this paper
• HDAC-mediated control of ERK- and PI3K-dependent TGF-β-induced extracellular matrix-regulating genes.

  2010cited by this paper
• TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma.

  2010cited by this paper
• TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

  2010cited by this paper
• TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma.

  2009cited by this paper
• TGFbeta in Cancer.

  2008cited by this paper
• HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different origin.

  2008cited by this paper
• Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation.

  2007cited by this paper
• The molecular mechanism of HDAC inhibitors in anticancer effects.

  2006influential reference
• Dynamic changes in chromatin acetylation and the expression of histone acetyltransferases and histone deacetylases regulate the SM22alpha transcription in response to Smad3-mediated TGFbeta1 signaling.

  2006cited by this paper
• Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells

  2006cited by this paper
• Histone deacetylases (HDACs): characterization of the classical HDAC family.

  2003influential reference
• HDAC inhibitors for the treatment of cancer.

  2003influential reference
• A Nuclear Antagonistic Mechanism of Inhibitory Smads in Transforming Growth Factor-β Signaling*

  2002cited by this paper
• TGF beta inhibition of Cdk4 synthesis is linked to cell cycle arrest.

  1993cited by this paper
• TGFβ inhibition of Cdk4 synthesis is linked to cell cycle arrest

  1993cited by this paper

• HDAC6 inhibition through WT161 synergizes with temozolomide, induces apoptosis, reduces cell motility, and decreases β-catenin levels in glioblastoma cells

  2025cites this paper
• Breaking down glioma primary cilia disassembly

  2025cites this paper
• How histone modifications influence cellular radiosensitivity: Pharmaceutically targeting epigenetic regulators as a promising avenue to overcome radioresistance

  2025cites this paper
• Epigenetic regulation of histone modifications in glioblastoma: recent advances and therapeutic insights

  2025cites this paper
• The Pivotal Role of Irradiation-induced Autophagy Mechanisms in Glioma Therapy.

  2025cites this paper
• Precision Population Cancer Medicine in Brain Tumors: A Potential Roadmap to Improve Outcomes and Strategize the Steps to Bring Interdisciplinary Interventions

  2024cites this paper
• The Role of HDAC6 in Glioblastoma Multiforme: A New Avenue to Therapeutic Interventions?

  2024cites this paper
• Cancer epigenetics: from laboratory studies and clinical trials to precision medicine

  2024cites this paper
• Advances in the Mechanistic Study of the Control of Oxidative Stress Injury by Modulating HDAC6 Activity

  2023cites this paper
• Role of AT‐rich interaction domain 1A in gastric cancer immunotherapy: Preclinical and clinical perspectives

  2023cites this paper
• Emerging trends in post-translational modification: Shedding light on Glioblastoma multiforme.

  2023cites this paper
• Recent advancement of HDAC inhibitors against breast cancer

  2023cites this paper
• The Potential of Senescence as a Target for Developing Anticancer Therapy

  2023cites this paper
• Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy

  2023cites this paper
• Ricolinostat suppresses proliferation, promotes apoptosis, and enhances the antiproliferative activity of topoisomerase inhibitors in cervical cancer cells

  2022cites this paper
• HDAC6 promotes aggressive development of liver cancer by improving egfr mRNA stability

  2022cites this paper
• Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance

  2022cites this paper
• Epigenetically Mediated Ciliogenesis and Cell Cycle Regulation, and Their Translational Potential

  2021cites this paper
• HDAC6-selective inhibitors enhance anticancer effects of paclitaxel in ovarian cancer cells.

  2021cites this paper
• Clinical advances in targeting epigenetics for cancer therapy

  2021cites this paper
• Targeting Several Biologically Reported Targets of Glioblastoma Multiforme by Assaying 2D and 3D Cultured Cells

  2021cites this paper
• HDAC6 Signaling at Primary Cilia Promotes Proliferation and Restricts Differentiation of Glioma Cells

  2021influential citation
• Potential new targets and drugs related to histone modifications in glioma treatment.

  2021cites this paper
• Silencing of Histone Deacetylase 6 Decreases Cellular Malignancy and Contributes to Primary Cilium Restoration, Epithelial-to-Mesenchymal Transition Reversion, and Autophagy Inhibition in Glioblastoma Cell Lines

  2021cites this paper
• Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells

  2020cites this paper
• Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.

  2020cites this paper
• Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain

  2020cites this paper
• Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers.

  2020cites this paper
• Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma

  2020cites this paper
• Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models

  2019cites this paper
• Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells.

  2019cites this paper
• Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials

  2019cites this paper
• High‐selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma

  2019cites this paper
• Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways

  2018cites this paper
• Histone deacetylase 1 promotes glioblastoma cell proliferation and invasion via activation of PI3K/AKT and MEK/ERK signaling pathways.

  2018cites this paper
• Under explored epigenetic modulators: role in glioma chemotherapy

  2018cites this paper
• HDAC6 Brain Mapping with [18F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination

  2017cites this paper
• HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells.

  2017cites this paper
• Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury.

  2017cites this paper
• Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways.

  2017cites this paper
• Potentiel thérapeutique de l'inhibition d'HDAC6 en hypertension artérielle pulmonaire

  2017influential citation
• TDP-43/HDAC6 axis promoted tumor progression and regulated nutrient deprivation-induced autophagy in glioblastoma

  2017cites this paper
• HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.

  2016cites this paper
• Correlation between HDAC 6 expression and clinical features of renal cell carcinoma

  2016cites this paper
• HDACs and HDAC Inhibitors in Cancer Development and Therapy.

  2016cites this paper